Keytruda May Stay Competitive In Gastric Cancer Despite Losing Third-Line Claim
Executive Summary
While Opdivo’s first-line approval has altered the treatment landscape, Keytruda may expand its presence there in the next few years with new indications.
You may also be interested in...
Merck & Co.’s Keytruda Bounces Back In Advanced Gastric Cancer With Pivotal Success
The US major’s Keytruda has succeeded in a first-line advanced HER2-negative gastric cancer trial, which could help expand its label to a larger population and marks a positive reverse to past troubles in the indication.
Keytruda's Third-Line Gastric Cancer Indication Should Go, US FDA Panel Says
Citing changing therapeutic landscape and doubts about utility of checkpoint inhibitor monotherapy in this setting, advisory committee votes 6-2 against maintaining PD-1 inhibitor’s accelerated approval for third-line treatment of advanced gastric or gastroesophageal junction adenocarcinoma.
‘Dangling’ Accelerated Approvals: US FDA Flags Concerns About ‘Marginal’ Response Rates
Failed confirmatory trials for PD-1/L-1 inhibitor indications raise questions about marginal response rates in single-arm trials used to support accelerated approval, Oncology Center of Excellence leaders say in NEJM article that explains why the agency is taking six of these indications to its Oncologic Drugs Advisory Committee.